- Report
- January 2024
- 200 Pages
Global
From €4962EUR$5,000USD£4,117GBP
- Report
- December 2024
- 198 Pages
Global
From €5557EUR$5,600USD£4,611GBP
- Report
- May 2024
- 138 Pages
Global
From €6449EUR$6,499USD£5,351GBP
- Report
- June 2024
- 200 Pages
Global
From €6311EUR$6,360USD£5,236GBP
€7889EUR$7,950USD£6,545GBP
- Drug Pipelines
- April 2024
- 230 Pages
Global
From €2382EUR$2,400USD£1,976GBP
€2977EUR$3,000USD£2,470GBP
- Report
- October 2024
- 198 Pages
Global
From €3518EUR$3,545USD£2,919GBP
€3909EUR$3,939USD£3,243GBP
- Report
- May 2024
- 135 Pages
Global
From €6449EUR$6,499USD£5,351GBP
- Report
- June 2024
- 200 Pages
Global
From €6311EUR$6,360USD£5,236GBP
€7889EUR$7,950USD£6,545GBP
- Drug Pipelines
- April 2024
- 200 Pages
Global
From €1985EUR$2,000USD£1,647GBP
€2481EUR$2,500USD£2,058GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1588EUR$1,600USD£1,317GBP
€1985EUR$2,000USD£1,647GBP
- Report
- May 2024
- 420 Pages
Global
From €3275EUR$3,300USD£2,717GBP
- Report
- August 2024
- 100 Pages
Global
From €5904EUR$5,950USD£4,899GBP
- Report
- September 2022
- 247 Pages
Global
From €5210EUR$5,250USD£4,322GBP
- Report
- June 2022
- 207 Pages
Global
From €5210EUR$5,250USD£4,322GBP
- Report
- September 2024
- 120 Pages
China
From €5904EUR$5,950USD£4,899GBP
- Report
- January 2023
- 189 Pages
Global
From €3334EUR$3,360USD£2,766GBP
€4168EUR$4,200USD£3,458GBP
- Report
- January 2022
- 60 Pages
Global
From €3136EUR$3,160USD£2,602GBP
€3920EUR$3,950USD£3,252GBP
- Report
- January 2022
- 60 Pages
Global
From €3136EUR$3,160USD£2,602GBP
€3920EUR$3,950USD£3,252GBP
- Report
- October 2023
- 145 Pages
Global
From €3126EUR$3,150USD£2,593GBP
- Drug Pipelines
- December 2019
- 76 Pages
Global
From €3473EUR$3,500USD£2,882GBP
The Hepatocellular Carcinoma Drug market is a subset of the Oncology Drugs market. It is composed of drugs used to treat hepatocellular carcinoma (HCC), a type of liver cancer. These drugs are used to reduce the size of tumors, slow the growth of cancer cells, and reduce symptoms. Commonly used drugs include sorafenib, lenvatinib, and regorafenib. Other treatments, such as chemotherapy, radiation therapy, and surgery, may also be used in combination with these drugs.
The Hepatocellular Carcinoma Drug market is highly competitive, with many companies offering treatments for HCC. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. Other companies, such as AbbVie, AstraZeneca, and Eli Lilly, also offer treatments for HCC. Show Less Read more
